Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2004

01-08-2004

Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study

Authors: Danila Coradini, Cinzia Pellizzaro, Gabriella Abolafio, Marco Bosco, Ignazio Scarlata, Silvia Cantoni, Luca Stucchi, Sonia Zorzet, Claudia Turrin, Gianni Sava, Alberto Perbellini, Maria Grazia Daidone

Published in: Investigational New Drugs | Issue 3/2004

Login to get access
Metadata
Title
Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study
Authors
Danila Coradini
Cinzia Pellizzaro
Gabriella Abolafio
Marco Bosco
Ignazio Scarlata
Silvia Cantoni
Luca Stucchi
Sonia Zorzet
Claudia Turrin
Gianni Sava
Alberto Perbellini
Maria Grazia Daidone
Publication date
01-08-2004
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2004
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/B:DRUG.0000026247.72656.8a

Other articles of this Issue 3/2004

Investigational New Drugs 3/2004 Go to the issue

OriginalPaper

A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: A Southwest Oncology Group Study

OriginalPaper

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

OriginalPaper

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients

OriginalPaper

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

OriginalPaper

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

OriginalPaper

A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits